Clinical trial using interferon and a TLR3 agonist (rintatolimod) singly and in combination in HIV subjects well controlled with anti-retroviral drugs. Both clinical and lab opportunities in a country with a 10% HIV infection rate (clade C HIV).
Clinical trial project in planning phase with University of Capetown and industry (Bioclones (SA), Hemispherx Biopharma (US)). I expect it to be initiated prior to summer 2017.
| William Mitchell [Email] Pathology, Microbiology, and Immunology |
|
| Location |
Lima, Peru; Nashville, TN, USA; Maputo, Mozambique |
| Contacts | N/A |
| Program Type |
Research, Training or Education |
| Funding Type |
Internships |
| Region |
Africa |
| Global Health Topics |
Basic Sciences, Infectious Diseases |
| Eligibility |
Graduate students (non-clinical); Medical students (MD); Nursing students (MSN, DNP); Post-doctoral students, residents, or trainees |
| Program Length |
Flexible, depending on the individuals interests and needs |
| VU Affiliation |
The program is not affiliated with Vanderbilt. |
| Language(s) |
The program does not have a language requirement. |